Kolexia
Loriot Yohann Oncologie médicale
Loriot Yohann
Oncologie médicale
Gustave-Roussy
Villejuif, France
639 Activités
55 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Tumeurs de la prostate Tumeurs de la vessie urinaire Métastase tumorale Tumeurs prostatiques résistantes à la castration Carcinome transitionnel Tumeurs urologiques Néphrocarcinome Tumeurs du poumon

Collaborateurs

Voir plus
Fizazi Karim
Fizazi Karim
Gustave-Roussy, Villejuif, France
Massard Christophe
Massard Christophe
Gustave-Roussy, Villejuif, France
Albiges Laurence
Albiges Laurence
Gustave-Roussy, Villejuif, France
Flechon Aude
Flechon Aude
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
MSD
21 collaboration(s)
Dernière en 2023
Astellas
20 collaboration(s)
Dernière en 2023
Janssen
19 collaboration(s)
Dernière en 2023
Roche
18 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
The New England journal of medicine   08 mars 2024
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions.
Nature reviews. Clinical oncology   29 février 2024
RAGNAR: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
Essai Clinique (Janssen)   27 février 2024
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions
Essai Clinique (Janssen)   27 février 2024
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.
European urology   27 février 2024
THOR: A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
Essai Clinique (Janssen)   27 février 2024
TROPHY U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Essai Clinique (Gilead)   20 février 2024
PROOF302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Essai Clinique (QED Therapeutics, Inc.)   16 février 2024
IMvigor130: A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Essai Clinique (Roche)   31 janvier 2024
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301): An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Essai Clinique (Astellas)   31 janvier 2024